Navigation Links
DSM Joins International Response to Flooding in Australia
Date:1/27/2011

PARSIPPANY, N.J., Jan. 27, 2011 /PRNewswire/ -- Significant flooding occurred in many areas of Queensland during late December 2010 and early January 2011.  Thousands of residents were affected.  A disaster relief appeal, the 'Premier's Disaster Relief Appeal', was launched on 29 December 2010, by Premier of Queensland, Anna Bligh.  DSM recognizes the efforts of Queenslanders who pitched in to help their fellow citizens clean-up in the wake of the floods and help families in need, many of whom lost everything.  

In May of 2010 DSM announced the signing of agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.  Currently under construction the facility will be located on the Princess Alexandra Hospital Campus, 5.5 kilometers from the center of Brisbane. Karen King, President of DSM Biologics commented, "We are extremely concerned about the effects of the severe flooding in Queensland and the need for support of those impacted."  

Professor Peter Gray, Director of the Australian Institute of Bioengineering & Nanotechnology which is based in Queensland, visited DSM soon after the flooding.  According to Professor Gray, "The relief appeal will make a significant difference by helping many in need as Queensland battles to recover from the flooding.  I am delighted to have DSM among our supporters."  Alexander Wessels, President and CEO, DSM Pharmaceutical Products, stated, "As a responsible corporate citizen around the world, DSM is committed to the communities in which we work and live. This is our humble gesture to aid those in need through the auspices of the Premier's appeal."

For more information about supporting the Premier's Disaster Relief Appeal, visit www.qld.gov.au/floods/  

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com For more information:DSMGuy TieneDirector, marketing and Communicationstel. +1 973 257 8160guy.tiene@dsm.com  DSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
2. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
3. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
4. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as COO
5. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
6. Joseph J. LaRosa Joins Nycomed US Inc.
7. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
8. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
9. LitePoint Joins Continua Health Alliance
10. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
11. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Dr. David ... in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... is an online directory that recognizes local physicians and dentists who have earned ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for ... expert sit stand solutions representative to the Minneapolis Home and Garden Show which is ... event that is garnering national attention is the Minneapolis Convention Center. , From ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company ... announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d ...
Breaking Medicine News(10 mins):